Drug Trial Radar · NCT05910827
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
398
Planned (sponsor's estimate)
Start
Feb 5, 2024
Primary completion
Dec 1, 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Hummingbird BioscienceIndustry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Jun 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers
Conditions
- Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
- Advanced Head and Neck Squamous Cell Carcinoma
- Advanced Esophageal Squamous Cell Carcinoma
- Cervical Squamous Cell Carcinoma
- Advanced Cutaneous Squamous Cell Carcinoma
- Nasopharyngeal Cancinoma (NPC)
- Squamous Cell Carcinoma
Interventions
HMBD-001Drug
HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly
DocetaxelDrug
Docetaxel 75 mg/m\^2 or 60 mg/m IV once every 3 weeks
CetuximabDrug
Cetuximab 250 mg/m\^2 weekly, with or without 400 mg/m\^2 IV loading dose at C1D1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Nature of Adverse Events (AEs)Time frame: From the time the Informed Consent Form (ICF) is signed until 30 days after last dose of study treatment
- Number of participants with dose-limiting toxicities (DLTs) - applicable to part ATime frame: From date of enrollment (first dosing) until the end of Cycle 1 (each cycle is 21 days)
- Six months progression-free survival (PFS) - applicable to part BTime frame: From date of enrollment (first dosing) until disease progression or death, assessed up to 6 months
Locations
20 sites in 5 countries. Site status is shown where the registry gives one.
GenesisCare North Shore
Sydney, New South Wales, Australia · Withdrawn
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
ICON Cancer Centre South Brisbane
Brisbane, Queensland, Australia · Withdrawn
Greenslopes Private Hospital
Greenslopes, Queensland, Australia · Recruiting
Southern Oncology Clinical Research Unit
Adelaide, South Australia, Australia · Recruiting
Peninsula & South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia · Recruiting
Cabrini Health
Malvern, Victoria, Australia · Withdrawn
Linear Clinical Research
Perth, Western Australia, Australia · Recruiting
The Institute of Oncology, ARENSIA Exploratory Medicine Phase I Unit
Chisinau, Moldova · Recruiting
National Cancer Centre Singapore
Singapore, Singapore · Recruiting
Tan Tock Seng Hospital
Singapore, Singapore · Recruiting
Chungbuk National University Hospital
Cheongju-si, South Korea · Recruiting
CHA Bundang Medical Center, CHA University
Seongnam-si, South Korea · Recruiting
Korea University Anam Hospital
Seoul, South Korea · Recruiting
Severance Hospital
Seoul, South Korea · Recruiting
The Catholic University of Korea St. Vincent's Hospital
Suwon, South Korea · Recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan · Recruiting
National Cheng Kung University Hospital
Tainan, Taiwan · Recruiting
Taipei Medical University - Shuang Ho Hospital
Taipei, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.